Date of preparation April 2014 │BRI001081 ACC.14 Annual Scientific Sessions of the American College of Cardiology Washington DC 29-31 March 2014
Date of preparation April 2014 │BRI001081
ACC.14Annual Scientific Sessions of the American College of Cardiology
Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
Disclaimer
• AstraZeneca abides by the Medicines Australia Code of Conduct (Edition 17) and AstraZeneca Global Policies, and as such will not engage in the promotion of unregistered products or unapproved indications.
• These highlights have been suggested by a group of cardiologists who attended ACC.14, compiled by an external medical writer and sponsored by AstraZeneca.
• Statements of fact and opinions expressed are those of the speakers individually and, unless expressly stated to the contrary, are not the opinion or position of AstraZeneca. AstraZeneca does not endorse or approve, and assumes no responsibility for, the content, accuracy, or completeness of the information presented. Presentations are intended for educational purposes only and do not replace independent professional judgement.
• Please refer to the appropriate approved Product Information before prescribing any agents mentioned in these highlights.
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
CORP-2 study: Colchicine for recurrences of pericarditis
Commentary:
Associate Professor Chris ZeitzQueen Elizabeth Hospital, Adelaide
Late-breaking trial
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Lancet Online
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Recurrence halved from 42.5% to 21.6%
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Colchicine well tolerated
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
• Colchicine is well established as a treatment for initial, or first recurrences of, pericarditis.
• The remarkable efficacy and good tolerability of colchicine demonstrated in CORP-2 consolidates its role: it should now be considered as a first-line therapy.
Commentary: Associate Professor Chris Zeitz